News Home

Analyst Rating: Will Heron Therapeutics Inc (HRTX) Stock Beat the Market?

Wednesday, December 08, 2021 11:59 AM | InvestorsObserver Analysts
Analyst Rating: Will Heron Therapeutics Inc (HRTX) Stock Beat the Market?

Analysts who follow Heron Therapeutics Inc (HRTX) on average expect it to climb 286.42% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns Heron Therapeutics Inc an Analyst Ranking of 74, which means it ranks higher than 74 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating HRTX a Strong Buy today. Find out what this means to you and get the rest of the rankings on HRTX!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Heron Therapeutics Inc Stock Today?

Heron Therapeutics Inc (HRTX) stock is trading at $8.54 as of 11:57 AM on Wednesday, Dec 8, a decline of -$0.48, or -5.29% from the previous closing price of $9.02. The stock has traded between $8.50 and $8.95 so far today. Volume today is less active than usual. So far 1,277,256 shares have traded compared to average volume of 1,974,782 shares. Click Here to get the full Stock Report for Heron Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App